Effect of memantine on prolonging safe driving in early AD: a pilot study - Holland PJ, Tappen RM, Newman DO, Freeman-Costin KC, Fisher LJ.
BACKGROUND: To determine the feasibility of conducting an RCT on the potential effectiveness of memantine hydrochloride in prolonging safe driving in mild AD. METHODS: A placebo-controlled, double blind randomized trial was conducted. Forty-three i... (Source: SafetyLit)
Source: SafetyLit - December 18, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Role of Memantine in the Prophylactic Treatment of Migraine Role of Memantine in the Prophylactic Treatment of Migraine
Memantine has been used off-label for the prevention of episodic migraine. Does current evidence support its efficacy and safety for migraine prophylaxis?Headache (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2021 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Author Q & A: Ketamine as a treatment for depression
In this interview with Doctoral Researcher Rebecca Dean and Professor Andrea Cipriani we learn more about two reviews investigating the use of ketamine as a treatment for depression recently published through Cochrane ’s Common Mental Disorders Group.Tell us about this Cochrane ReviewThis review is an update of a Cochrane review published in 2015, investigating the use of ketamine and other glutamate receptor modulators as a treatment for unipolar depression (also known as major depressive disorder).Since 2015, a lot of research has been published in this area and the FDA has recently licensed esketamine (Spravato) for u...
Source: Cochrane News and Events - October 7, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia
Wednesday, February 3, 2021 (Source: Cochrane News and Events)
Source: Cochrane News and Events - February 3, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Memantine misuse and social networks: a content analysis of internet self-reports - Natter J, Michel B.
PURPOSE: Memantine is a N-methyl-D-aspartate (NMDA) receptor antagonist currently used for moderate-to-severe Alzheimer's disease. Although the risk of memantine abuse is very low, other NMDA receptor antagonists, such as phencyclidine and ketamine, are we... (Source: SafetyLit)
Source: SafetyLit - July 4, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules
BAUDETTE, Minn., March 2, 2020 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Foo... Biopharmaceuticals, Neurology, FDA ANI Pharmaceuticals, Memantine, Alzheimer's (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 2, 2020 Category: Pharmaceuticals Source Type: news

Class 4 Medicines Defect Information: Memantine 10mg Film-Coated Tablets, PL 20416/0260
Crescent Pharma Ltd has informed the Medicines and Healthcare products Regulatory Agency (MHRA) of... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 25, 2020 Category: Drugs & Pharmacology Source Type: news

Allergan Signs $750 Mln Settlement With Purchasers of Alzheimer's Drug Namenda Allergan Signs $750 Mln Settlement With Purchasers of Alzheimer's Drug Namenda
Purchasers of Allergan Plc ' s Namenda asked a federal judge on Tuesday to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer ' s medication off the market.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Allergan signs $750 million settlement with purchasers of Alzheimer's drug Namenda
Purchasers of Allergan Plc's Namenda asked a federal judge on Tuesday to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer's medication off the market. (Source: Reuters: Health)
Source: Reuters: Health - December 24, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Alzheimer's Drug Reduces Chagas Disease Infection in Mice
The drug, called memantine, could enter clinical trials to determine its effectiveness in humans. (Source: The Scientist)
Source: The Scientist - December 1, 2019 Category: Science Tags: The Literature Source Type: news